Key Proteo

Key Proteo is a pioneering proteomics diagnostics company dedicated to expanding newborn screening programs by identifying treatable genetic disorders at an early stage. The company aims to improve and broaden current newborn screening initiatives, enabling early intervention in genetic diseases before their clinical manifestations. Specializing in the use of alternative peptide biomarkers, Key Proteo conducts multiplex analyses of any ultra-low-abundance proteins in a few drops of blood (DBS) via mass spectrometry. With this innovative technology, Key Proteo targets new or existing genetic disorders, altering their clinical trajectories to ensure better quality of life for patients.